<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347579</url>
  </required_header>
  <id_info>
    <org_study_id>NL35546.068.11</org_study_id>
    <nct_id>NCT02347579</nct_id>
  </id_info>
  <brief_title>Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain</brief_title>
  <acronym>BrainEXPain</acronym>
  <official_title>Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Complex Regional Pain syndrome Type I (CRPS-I) is a chronic progressive disease. Patients
      experience dramatic decline of overall well-being, despite the absence of any apparent
      physical cause. The main symptoms are hypersensitivity to pain (hyperalgesia) and
      experiencing normal tactile stimulation as painful (allodynia) in the absence of peripheral
      nerve damage. The debate on the aetiology of CRPS-I is still open.

      The therapy offered to CRPS-I patients is diverse and can involve invasive and non-invasive
      interventions. Current (inter)national guidelines recommend physiotherapy as the best
      non-invasive treatment for rehabilitation. Recently, cognitive and behavioural Graded
      Exposure in Vivo (GEXP) therapy aimed at reducing pain-related fear was found to be effective
      (De Jong et al. 2005), and more effective than standard physical therapy (ReMOVE study,
      articles in preparation). By reducing pain-related fear EXP might reconcile motor output and
      sensory feedback.

      Another type of pain is lower back pain (LBP), which affects 70% to 85% of general
      population, but usually heals within 12 weeks in 90% of patients. The rest of the patients
      suffer from intractable, chronic LBP despite no evident organic abnormality. Research shows
      that also in these patients cognitive and behavioural aspects of pain are important and
      related to physical performance and self-reported disability (Vlaeyen et al., 2000). Several
      studies have demonstrated the success of GEXP in this patient group: GEXP resulted in
      improvements in pain-related fear, catastrophizing, performance of daily relevant activities,
      and in pain intensity (Leeuw et al., 2008).

      This study aims to investigate the effect of GEXP on brain regions involved in the processing
      of harmless tactile stimuli in CRPS-I and CLBP patients, as well as its effect on tactile
      discrimination thresholds. We hypothesize that GEXP will induce 1) an improvement of tactile
      discrimination thresholds, 2) a functional reorganization of primary and secondary
      somatosensory cortex (in regions related to the affected limb in CRPS-I; and to the back in
      LBP), 3) changes in activation of emotional brain circuits during non-noxious stimulation, 4)
      changes in resting state connectivity between emotional and sensory brain areas, 5) changes
      in measures reflecting white matter integrity. No systematic changes are expected in the
      healthy controls.

      Patients diagnosed with CRPS-I and CLBP will participate in a Magnetic Resonance Imaging
      (MRI) experiment. In this observational study, we examine the effects of GEXP treatment that
      all patients receive as part of usual care. Anatomical as well as diffusion-weighted and
      T2*-weighted (Blood oxygenation level dependent) MR images will be acquired. The study has a
      3x4 split plot design with group (CRPS-I patients and CLBP receiving GEXP treatment / healthy
      controls) as between-subjects variable and time (pre-, during, post-treatment and follow-up)
      as within-subject variable.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline blood oxygenation level dependent (BOLD) signal (fMRI) during tactile stimulation and during rest</measure>
    <time_frame>participants will be assessed repeatedly during the treatment; at baseline, at 5/6 weeks after start of treatment, at end of treatment (approximately 10 weeks after start) and at follow-up (6 months after end of treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline diffusion MRI measures (fractional anisotropy, neurite density, orientation dispersion)</measure>
    <time_frame>participants will be assessed repeatedly during the treatment; at baseline, at 5/6 weeks after start of treatment, at end of treatment (approximately 10 weeks after start) and at follow-up (6 months after end of treatment)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline tactile discrimination threshold in mm</measure>
    <time_frame>participants will be assessed repeatedly during the treatment; at baseline, at 5/6 weeks after start of treatment, at end of treatment (approximately 10 weeks after start) and at follow-up (6 months after end of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pain-related fear (TSK, PHODA)</measure>
    <time_frame>participants will be assessed repeatedly during the treatment; at baseline, at 5/6 weeks after start of treatment, at end of treatment (approximately 10 weeks after start) and at follow-up (6 months after end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pain catastrophizing (PCS)</measure>
    <time_frame>participants will be assessed repeatedly during the treatment; at baseline, at 5/6 weeks after start of treatment, at end of treatment (approximately 10 weeks after start) and at follow-up (6 months after end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline pain intensity level as assessed on visual analog scale</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Patients with CRPS</arm_group_label>
    <description>Patients with Complex Regional Pain Syndrome, Type I</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with CLBP</arm_group_label>
    <description>Patients with chronic low back pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        People diagnosed with CRPS, type I, and people with chronic low back pain (CLBP) are target
        population for this study. A group of healthy controls matched for age, gender and
        handedness will also take part in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        CRPS-I patients:

          -  A clinical diagnosis of CRPS-I according to 'the Budapest criteria' for research
             purposes (Harden et al., 2007):

               -  Continuing pain, which is disproportionate to any inciting event

               -  Must report at least one symptom in all of the four following categories:

                    -  Sensory: Reports of hyperesthesia and/or allodynia

                    -  Vasomotor: Reports of temperature asymmetry and/or skin color changes and/or
                       skin color asymmetry

                    -  Sudomotor / Edema: Reports of edema and/or sweating changes and/or sweating
                       asymmetry

                    -  Motor / Trophic: Reports of decreased range of motion and/or motor
                       dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail,
                       skin)

               -  Must display at least one sign at time of evaluation in two or more of the
                  following categories:

                    -  Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light
                       touch and/or temperature sensation and/or deep somatic pressure and/or joint
                       movement)

                    -  Vasomotor: Evidence of temperature asymmetry and/or skin color changes
                       and/or asymmetry

                    -  Sudomotor / Edema: Evidence of edema and/or sweating changes and/or sweating
                       asymmetry

                    -  Motor / Trophic: Evidence of decreased range of motion and/or motor
                       dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail,
                       skin)

               -  There is no other diagnosis that better explains the signs and symptoms

          -  Unilateral localization on upper or lower extremity

        CLBP patients:

          -  Experience of non-specific lower back pain for at least three months

          -  No other diagnosis better explaining the signs and symptoms. both patient groups:

          -  Report of substantial fear of movement/(re)-injury

          -  Age between 18 and 65 years

          -  Stable medication

        healthy controls:

          -  Age between 18 and 65 years

          -  Matched for age, gender and handedness

        Exclusion Criteria:

        patients and healthy controls:

          -  Neuropathy of the upper or lower extremities

          -  MRI incompatible health condition (e. g. pacemaker, metal prosthetic devices)

          -  Psychiatric condition and ongoing medication that would alter emotional/sensory
             processing

          -  Previous tactile impairment in the upper or lower extremity caused by:

               -  damage to the sensory apparatus

               -  CNS lesion

        healthy controls:

        â€¢ (history of) CRPS or other chronic pain syndromes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
    <mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

